MetaCap

Lexeo Therapeutics (LXEO) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $228.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LXEO-33.78%SCTX-36.37%
+103%+28%-48%
Jul 27, 20261 yearNov 20, 2026
LXEO-28.33%SCTX-38.04%
+81%+19%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LXEO versus SCTX key metrics
MetricLXEOSCTX
Share price$2.96$12.07
Market cap$245.05M$228.58M
1-day change+0.34%-8.70%
YTD return-70.19%—
1-year return-67.33%—
EPS (TTM)$-1.13$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-100.00M—
52-week high$10.99$39.60
52-week low$2.55$12.00
Distance from 52-week high-73.07%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+748.31%+372.25%
Average volume1.98M403.27K
Shares outstanding82.79M18.94M
Employees6877
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

LXEO vs SCTX FAQ

Which is bigger, Lexeo Therapeutics or Scribe Therapeutics?

Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $228.58M for Scribe Therapeutics (SCTX).

Are Lexeo Therapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons